Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma.

Pathology Oncology Research : POR
Hulya Sahin OzkanHandan Kaya

Abstract

Tumor immune microenvironment (TIME) is a significant prognostic parameter for triple negative breast carcinomas (TNBC) due to being a target for immunotherapeutic agents and its essential role during the cancer immunoediting process. In this study, CD8, FOXP3, CD163, PD-L1/SP142 and PD-L1/SP263 antibodies were examined in a sample of 51 TNBC cases. Patients who received neoadjuvant therapy were excluded. CD8, FOXP3 and CD163 antibodies were evaluated separately in intratumoral area (ITA) and tumor stroma (TS). PD-L1 status was also examined in tumor cells (TC) and immune cells (IC) using both SP142 and SP263 antibodies. In multivariate Cox regressions, the only antibody that was found to be significantly associated with survival was SP142. SP142-positivity in TC and IC was related to increased overall survival. Higher CD163 expression in ITA and SP263-positivity in IC were associated with younger age. Lymphatic/angioinvasion was more frequent in cases with negative/low CD8 and FOXP3 expressions. Moreover, metastatic axillary lymph node(s) was associated with negative/low FOXP3 expression in TS. CD8, FOXP3, CD163, SP142 and SP263 expressions were positively correlated with each other, except a mild discordance caused by CD163 i...Continue Reading

References

Aug 17, 2004·Immunity·Gavin P DunnRobert D Schreiber
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Lisa A CareyRobert C Millikan
Dec 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gaynor J BatesAlison H Banham
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea MerloAndrea Balsari
Apr 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Elizabeth H HammondAntonio C Wolff
Jun 18, 2010·Breast Cancer Research and Treatment·Sahar M A MahmoudAndrew R Green
Jul 20, 2010·Immunological Reviews·Loise M FranciscoArlene H Sharpe
Nov 10, 2010·Breast Cancer Research : BCR·Reinaldo D Chacón, María V Costanzo
Nov 16, 2010·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Sunil BadveJorge S Reis-Filho
Feb 10, 2011·The Oncologist·Charles M Perou
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sahar M A MahmoudAndrew R Green
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Jun 7, 2011·Cancer Immunology, Immunotherapy : CII·Sylvain LadoireFrançois Ghiringhelli
Mar 17, 2012·Breast Cancer Research : BCR·Shuzhen LiuTorsten O Nielsen
Oct 19, 2012·Acta Oncologica·Soohyeon LeeYoung-Hyuck Im
Aug 8, 2013·The American Journal of Pathology·Olav EngebraatenAnne-Lise Børresen-Dale
Oct 12, 2013·The Journal of Pathology·Brian D Lehmann, Jennifer A Pietenpol
Mar 22, 2014·Molecular and Clinical Oncology·Miki TakenakaMasayoshi Kage
May 21, 2014·Breast Cancer Research and Treatment·S MuenstS D Soysal
Jun 12, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H R AliC Caldas
Aug 8, 2014·The Cancer Journal·Miguel F Sanmamed, Lieping Chen
Sep 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew D BursteinPowel H Brown
Sep 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R SalgadoUNKNOWN International TILs Working Group 2014
Feb 12, 2015·Oncotarget·Renaud SabatierFrançois Bertucci
Sep 9, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A I Hida, Y Ohi
Mar 11, 2016·Breast Cancer Research and Treatment·Hirofumi MatsumotoJabed Iqbal
Aug 20, 2016·JAMA Oncology·Patricia GauleDavid L Rimm

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

TIL

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.